Approval · Notice of Compliance 12518 · 2011
TRAJENTA: Notice of Compliance 12518
Issued July 28, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12518
- Date
- July 28, 2011
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Oral Antihyperglycemic Agent: DPP-4 Inhibitor: Incretin Enhancer
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TRAJENTA | 02370921 | Marketed |
Medicinal ingredients
- LINAGLIPTIN 5 MG per TAB